Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

SurgePays (SURG) Gets a Buy from Ascendiant

Tipranks - Tipranks - Tue Jun 17, 2025

Ascendiant analyst Edward Woo maintained a Buy rating on SurgePays (SURG – Research Report) today and set a price target of $9.00. The company’s shares closed last Friday at $2.58.

Confident Investing Starts Here:

According to TipRanks, Woo is an analyst with an average return of -8.6% and a 32.72% success rate. Woo covers the Healthcare sector, focusing on stocks such as GRI Bio, Envoy Medical, and Cingulate Inc.

SurgePays has an analyst consensus of Moderate Buy, with a price target consensus of $8.75.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.80 and a one-year low of $1.05. Currently, SurgePays has an average volume of 1.67M.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, David Allen May, a Director at SURG sold 63,000.00 shares for a total of $177,030.00.

Read More on SURG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).